SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model

• Published in: Nature communications Vol. 13; no. 1; p. 4416
• Main Authors: Lieber, Carolin M., Cox, Robert M., Sourimant, Julien, Wolf, Josef D., Juergens, Kate, Phung, Quynh, Saindane, Manohar T., Smith, Meghan K., Sticher, Zachary M., Kalykhalov, Alexander A., Natchus, Michael G., Painter, George R., Sakamoto, Kaori, Greninger, Alexander L., Plemper, Richard K.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29-07-2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13/106; 13/107; 14/19; 45/90; 45/91; 59; 631/326/22/1295; 631/326/596/1296; 631/326/596/2563; 631/326/596/4130; 64; 96; Antiviral agents; Antiviral drugs; Coronaviruses; COVID-19; Disease transmission; Epithelium; Hamsters; Humanities and Social Sciences; Life Sciences; Lungs; multidisciplinary; Mustela; Organoids; Pathogenicity; Pathogens; Respiratory tract; Science; Science (multidisciplinary); Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Viral diseases; Viruses
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-022-32045-1

SARS-CoV-2 variants of concern (VOC) have triggered infection waves. Oral antivirals such as molnupiravir promise to improve disease management, but efficacy against VOC delta was questioned and potency against omicron is unknown. This study evaluates molnupiravir against VOC in human airway epithelium organoids, ferrets, and a lethal Roborovski dwarf hamster model of severe COVID-19-like lung injury. VOC were equally inhibited by molnupiravir in cells and organoids. Treatment reduced shedding in ferrets and prevented transmission. Pathogenicity in dwarf hamsters was VOC-dependent and highest for delta, gamma, and omicron. All molnupiravir-treated dwarf hamsters survived, showing reduction in lung virus load from one (delta) to four (gamma) orders of magnitude. Treatment effect size varied in individual dwarf hamsters infected with omicron and was significant in males, but not females. The dwarf hamster model recapitulates mixed efficacy of molnupiravir in human trials and alerts that benefit must be reassessed in vivo as VOC evolve.
Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned. Here the authors evaluate molnupiravir against variant of concern in numerous models, including human airway epithelium organoids, ferrets and Roborovski dwarf hamsters.